Generated October 17, 2026.
Overview
VHT and XLV are both large, passively managed healthcare equity ETFs tracking different healthcare indexes. The key distinction is breadth: VHT's index includes mid-cap and smaller healthcare companies alongside large caps, while XLV focuses exclusively on large-cap names in the S&P 500.
How they differ
VHT and XLV differ first in index methodology and universe size. VHT's MSCI index captures healthcare across the full investable market with concentration limits (25% and 50% caps on individual and cumulative top holdings), while XLV's sector index pulls only from S&P 500 constituents, tilting exposure toward mega-cap names. XLV yields 1.45% compared to VHT's 1.18%, a difference of 0.27% percentage points. XLV holds a larger asset base at $44.3B versus VHT's $18.9B, and is slightly cheaper to own at 0.08% versus 0.09%. VHT shows marginally higher beta at 0.57 compared to XLV's 0.52, reflecting greater sensitivity to market moves—likely due to broader exposure beyond the largest-cap names.
Who each is best for
VHT: Fits investors seeking diversified healthcare exposure that extends beyond mega-cap names, valuing the ability to capture mid-cap healthcare growth and innovation outside the S&P 500 core.
XLV: Fits investors who want large-cap healthcare sector exposure aligned with S&P 500 holdings and are comfortable with a heavier weighting toward dominant healthcare companies.
Key risks to know
- Index concentration and cap effects. XLV's S&P 500 sector index concentrates exposure in a smaller number of mega-cap healthcare firms; VHT's broader market index with 25/50 concentration limits distributes risk more evenly. An outperformance or underperformance by the handful of largest healthcare names will have outsized impact on XLV returns.
- Different company profiles drive style drift. VHT's exposure to mid-cap and smaller healthcare companies introduces different growth, profitability, and volatility characteristics than XLV's large-cap anchors. Holdings and sector weightings between the two are not identical, making them imperfect substitutes for the same "healthcare bet."
- Large-cap healthcare regulatory and valuation risk. Both funds are exposed to healthcare policy changes and drug pricing pressure, but XLV's concentration in mega-cap pharmaceutical, biotech, and medical device manufacturers means regulatory headwinds or patent cliffs at a few major holdings can meaningfully drag returns.
Bottom line
If you want comprehensive healthcare market exposure including mid-cap innovators and a more balanced holding structure, VHT's broader index construction stands out. If you prefer to track large-cap healthcare as defined by the S&P 500 and don't mind the higher yield and slightly lower cost, XLV aligns with that focus. Both offer minimal expense ratios and quarterly dividends, so the choice hinges on whether you want the full healthcare market or just its largest players. Past performance does not predict future returns.
AI-generated analysis for educational purposes only. Verify important details independently; past performance does not guarantee future results.